Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 5—May 2020
Synopsis

Clinical Outcomes of Patients Treated for Candida auris Infections in a Multisite Health System, Illinois, USA

Kellie Arensman, Jessica L. Miller, Anthony Chiang, Nathan Mai, Joseph Levato, Erik LaChance, Morgan Anderson, Maya Beganovic, and Jennifer Dela PenaComments to Author 
Author affiliations: Advocate Lutheran General Hospital, Park Ridge, Illinois, USA (K. Arensman, M. Beganovic, J. Dela Pena); Advocate South Suburban Hospital, Hazel Crest, Illinois, USA (J.L. Miller); Advocate Trinity Hospital, Chicago, Illinois, USA (J.L. Miller); Swedish Covenant Hospital, Chicago (A. Chiang); Advocate Christ Medical Center, Oak Lawn, Illinois, USA (N. Mai, J. Levato); Advocate Illinois Masonic Medical Center, Chicago (E. LaChance); Advocate Condell Medical Center, Libertyville, Illinois, USA (M. Anderson); Advocate Good Shepherd Hospital, Barrington, Illinois, USA (M. Anderson)

Main Article

Table 1

MICs of 28 Candida auris isolates from patients treated for C. auris infections in a multisite health system, Illinois, USA*

Antifungal drug MIC, µg/mL
0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 64 128 256 >256
Anidulafungin 3.6 64.3 28.6 3.6
Caspofungin 3.6 25.0 42.9 25.0 3.6
Micafungin 50.0 39.3 3.6 3.6 3.6
Fluconazole 39.3 35.7 10.7 3.6 3.6 3.6 3.6
Itraconazole 7.1 32.1 39.3 17.9 3.6
Posaconazole 10.7 50.0 25.0 14.3
Voriconazole 42.9 21.4 21.4 3.6 10.7
Amphotericin B 10.7 82.1 3.6
Flucytosine 17.9 71.4 10.7

*Values are percentage of isolates having the MIC shown. Shaded values are considered resistant on the basis of Centers for Disease Control and Prevention tentative C. auris breakpoints (22).

Main Article

References
  1. Satoh  K, Makimura  K, Hasumi  Y, Nishiyama  Y, Uchida  K, Yamaguchi  H. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009;53:41–4. DOIPubMedGoogle Scholar
  2. Lee  WG, Shin  JH, Uh  Y, Kang  MG, Kim  SH, Park  KH, et al. First three reported cases of nosocomial fungemia caused by Candida auris. J Clin Microbiol. 2011;49:3139–42. DOIPubMedGoogle Scholar
  3. Chowdhary  A, Sharma  C, Duggal  S, Agarwal  K, Prakash  A, Singh  PK, et al. New clonal strain of Candida auris, Delhi, India. Emerg Infect Dis. 2013;19:1670–3. DOIPubMedGoogle Scholar
  4. Magobo  RE, Corcoran  C, Seetharam  S, Govender  NP. Candida auris-associated candidemia, South Africa. Emerg Infect Dis. 2014;20:1250–1. DOIPubMedGoogle Scholar
  5. Emara  M, Ahmad  S, Khan  Z, Joseph  L, Al-Obaid  I, Purohit  P, et al. Candida auris candidemia in Kuwait, 2014. Emerg Infect Dis. 2015;21:1091–2. DOIPubMedGoogle Scholar
  6. Schelenz  S, Hagen  F, Rhodes  JL, Abdolrasouli  A, Chowdhary  A, Hall  A, et al. First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrob Resist Infect Control. 2016;5:35. DOIPubMedGoogle Scholar
  7. Calvo  B, Melo  AS, Perozo-Mena  A, Hernandez  M, Francisco  EC, Hagen  F, et al. First report of Candida auris in America: Clinical and microbiological aspects of 18 episodes of candidemia. J Infect. 2016;73:369–74. DOIPubMedGoogle Scholar
  8. Vallabhaneni  S, Kallen  A, Tsay  S, Chow  N, Welsh  R, Kerins  J, et al.; MSD. Investigation of the first seven reported cases of Candida auris, a globally emerging invasive, multidrug-resistant fungus—United States, May 2013–August 2016. MMWR Morb Mortal Wkly Rep. 2016;65:1234–7. DOIPubMedGoogle Scholar
  9. Heath  CH, Dyer  JR, Pang  S, Coombs  GW, Gardam  DJ. Candida auris sternal osteomyelitis in a man from Kenya visiting Australia, 2015. Emerg Infect Dis. 2019;25:192–4. DOIPubMedGoogle Scholar
  10. Adams  E, Quinn  M, Tsay  S, Poirot  E, Chaturvedi  S, Southwick  K, et al.; Candida auris Investigation Workgroup. Candida auris Investigation Workgroup. Candida auris in healthcare facilities, New York, USA, 2013–2017. Emerg Infect Dis. 2018;24:1816–24. DOIPubMedGoogle Scholar
  11. Sarma  S, Upadhyay  S. Current perspective on emergence, diagnosis and drug resistance in Candida auris. Infect Drug Resist. 2017;10:155–65. DOIPubMedGoogle Scholar
  12. Lone  SA, Ahmad  A. Candida auris-the growing menace to global health. Mycoses. 2019;62:620–37. DOIPubMedGoogle Scholar
  13. Osei Sekyere  J. Candida auris: A systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen. MicrobiologyOpen. 2018;7:e00578. DOIPubMedGoogle Scholar
  14. Kerins  JL, Tang  AS, Forsberg  K, Jegede  O, Ealy  M, Pacilli  M, et al. Rapid emergence of Candida auris in the Chicago region. Open Forum Infect Dis. 2018;5(S1):S28. DOIGoogle Scholar
  15. Hayden  MK, Dangana  TE, Yelin  RD, Schoeny  M, Bell  PB, Stanley  M, et al. Prevalence of Candida auris at body sites, characterization of skin microbiota, and relation of chlorhexidine gluconate (CHG) skin concentration to C. auris detection among patients at a high-prevalence ventilator-capable skilled nursing facility (vSNF) with established CHG bathing. Open Forum Infect Dis. 2019;6(S2):S25–6. DOIGoogle Scholar
  16. Lockhart  SR, Etienne  KA, Vallabhaneni  S, Farooqi  J, Chowdhary  A, Govender  NP, et al. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis. 2017;64:134–40. DOIPubMedGoogle Scholar
  17. Park  JY, Bradley  N, Brooks  S, Burney  S, Wassner  C. Management of patients with Candida auris fungemia at community hospital, Brooklyn, New York, USA, 2016–2018. Emerg Infect Dis. 2019;25:601–2. DOIPubMedGoogle Scholar
  18. Tsay  S, Welsh  RM, Adams  EH, Chow  NA, Gade  L, Berkow  EL, et al.; MSD. Ongoing transmission of Candida auris in health care facilities—United States, June 2016–May 2017. MMWR Morb Mortal Wkly Rep. 2017;66:514–5. DOIPubMedGoogle Scholar
  19. Bajpai  V, Govindaswamy  A, Sagar  S, Kumar  S, Garg  P, Xess  I, et al. Multidrug-resistant fungemia in critical care units: experience from a tertiary care hospital in India. Microb Drug Resist. 2019;mdr.2019.0021 [Epub ahead of print].
  20. Chow  NA, Gade  L, Tsay  SV, Forsberg  K, Greenko  JA, Southwick  KL, et al.; US Candida auris Investigation Team. Multiple introductions and subsequent transmission of multidrug-resistant Candida auris in the USA: a molecular epidemiological survey. Lancet Infect Dis. 2018;18:1377–84. DOIPubMedGoogle Scholar
  21. Biagi  MJ, Wiederhold  NP, Gibas  C, Wickes  BL, Lozano  V, Bleasdale  SC, et al. Development of high-level echinocandin resistance in a patient with recurrent Candida auris candidemia secondary to chronic candiduria. Open Forum Infect Dis. 2019;6:ofz262. DOIPubMedGoogle Scholar
  22. Tsay  S, Kallen  A, Jackson  BR, Chiller  TM, Vallabhaneni  S. Approach to the investigation and management of patients with Candida auris, an emerging multidrug‐resistant yeast. Clin Infect Dis. 2018;66:306–11. DOIPubMedGoogle Scholar

Main Article

Page created: April 16, 2020
Page updated: April 16, 2020
Page reviewed: April 16, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external